The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Avanir Pharmaceuticals's revenues will grow 85.0% and EPS will remain in the red.
The average estimate for revenue is $19.4 million. On the bottom line, the average EPS estimate is -$0.11.
Last quarter, Avanir Pharmaceuticals reported revenue of $17.4 million. GAAP reported sales were 74% higher than the prior-year quarter's $10.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at -$0.12. GAAP EPS were -$0.12 for Q2 against -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 94.2%, 50 basis points worse than the prior-year quarter. Operating margin was -88.8%, much better than the prior-year quarter. Net margin was -94.8%, much better than the prior-year quarter.
The full year's average estimate for revenue is $76.2 million. The average EPS estimate is -$0.39.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 188 members out of 250 rating the stock outperform, and 62 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Avanir Pharmaceuticals a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is buy, with an average price target of $5.60.
- Add Avanir Pharmaceuticals to My Watchlist.